Abstract
Purpose: To study the clinical efficiency of fluticasone furoate to fluticasone propionate + salmeterol in patients with bronchial asthma (BA), in combination with allergic rhinitis (AR).
47 patients with asthma uncontrolled flow in combination with the AR under observation were in 2012. 30 (63.8%) women and 17 (36.2%) of men aged 20 to 53 years, disease duration of 4 to 22 years. BA IV stage was in 15 (31.9%) and III in 32 (68.1%) cases. In 19 (40.4%) cfses with AR combined polypous etmoiditom. Was found allergic to house dust in 32 (68%) patients, pen pads - 27 (57.4%), house dust mite - 22 (46.8%), library dust - 9 (19.1%), animal hair - 13 (27.7%), grass pollen 8 (17%), weed 14 (29.8%), trees, 3 (6.4%). Increased IgE was noted in 39 (83%) patients showed a change spirography indicators of respiratory function grade 1 in 14 (29.8%), grade 2 23 (48.9%), grade 3 10 (21.3%) patients according to FEV1. According to the severity of asthma fluticasone propionate + salmeterol 50/250 or fluticasone propionate + salmeterol 50/500 2 times a day with fluticasone furoate 110 mg were prescribed daily for 8 weeks.
Results: All patients reported reduction of symptoms of asthma, rhinitis, full control was achieved in 11 (23.4%) cases, partially controlled for in 36 (76.6%) improved lung function. According rhinoscopy in 15 (31.9%) cases the appearance of polypoid etmoidita was reduced, nasal breathing was fully renewed.
Thus, these results show the effectiveness and safety of fluticasone propionate + salmeterol with fluticasone furoate taking in the treatment of asthma, combined with the AR.
- © 2013 ERS